Apnimed Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

Vol. 1Y

—

Shs. 5Y

—

Rev. 5Y

Div Yld LY

—

Div Yld TTM

—

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Key people

Lawrence Miller

Chairman of the Board, Chief Executive Officer, Scientific Founder

Luigi Montemurro

Scientific Founder, Chief Scientific Officer

Michael Rogers

Chief Financial Officer

Dennis Molnar

Chief Operating Officer, Director

Ted Harding

Chief Human Resource Officer · since 2024

Ronald Farkas

Chief Medical Officer

Graham Goodrich

Chief Commercial Officer · since 2024

URL

https://apnimed.com

IPO date

Jul 31, 2026

Employees

Domiciled in

Incorporated in

Valuation

No data to show